Celularity Inc

Celularity operates with a negative total equity of -$38.06 million and a cash and equivalents balance of $6.18 million, indicating a liquidity risk as its cash reserves are insufficient to cover its operating losses of -$61.31 million. The company's market capitalization of $26.27 million is significantly lower than its enterprise value to revenue ratio of 0.76, suggesting a low valuation relative to its revenue. Profitability metrics show a return on equity of 2.41%, which is below the typical thresholds for pharmaceutical companies, indicating weak returns relative to its equity base. The company's operating margin is negative, with operating income of -$61.31 million on revenue of $26.55 million, reflecting poor operational efficiency. Celularity's revenue is not segmented by geographic region or product line in the available data, making it difficult to assess geographic or product concentration risks. However, the company's reliance on a limited number of partnerships and product candidates suggests a high concentration risk in its business model. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. Analysts have assigned a mean price target of $6.00, which is significantly higher than the current market price of $0.91, suggesting potential upside if the company can achieve profitability or secure additional funding. Celularity faces low liquidity and dilution risks based on the absence of immediate filing-based flags. However, the company's negative net income of -$91.72 million and operating cash flow of -$13.25 million indicate a need for external financing, which could lead to future dilution. Recent events include the publication of financial results and analyst estimates, but no significant corporate actions or regulatory developments were reported in the available data. The company's ongoing research and development activities are likely to be a key focus for future growth.